Patented Cancer Treatment Should Be Canceled As Obvious, Petitioner Says
ALEXANDRIA, Va. — In a Feb. 13 petition for inter partes review (IPR), a drug company seeks cancellation of various claims of a patented method of treating prostate cancers involving prostate-specific...To view the full article, register now.
Already a subscriber? Click here to view full article